Form: 8-K

Current report filing

October 25, 2016

Exhibit 99.1

 

LOGO     

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2017

Revenue increased 13% to $465.4 million; also up 13% on a constant currency basis

GAAP diluted earnings per share of $0.54; non-GAAP diluted earnings per share of $0.62

Operating cash flow of $86.2 million in the first quarter

San Diego, October 25, 2016 – ResMed Inc. (NYSE: RMD) today announced results for its quarter ended September 30, 2016. Revenue for the quarter was $465.4 million, a 13 percent increase compared to the same period of the prior year. Excluding the contribution from the Brightree acquisition, revenue for the quarter was $432.4 million, a 5 percent increase.    

“We had a solid start to our fiscal year with 13 percent constant currency revenue growth led by our Brightree software offerings and global device sales,” said Mick Farrell, ResMed’s chief executive officer. “We continue to demonstrate the value of our solutions, and earlier today, announced the world’s largest study on patient adherence. During the quarter, we drove consumer sleep awareness through a new U.S. media partnership, and sponsored a positive clinical study showing that non-invasive ventilation significantly reduces the risk of re-hospitalization and death for COPD.”

Farrell concluded, “In 2017, we continue to focus on developing and commercializing new, innovative products and solutions that improve patient outcomes, create efficiencies for our customers, and help physicians and providers better manage chronic disease and lower healthcare costs. We have an exciting pipeline of new products, and look forward to bringing them to market.”

Analysis of first quarter results

First quarter revenue in the Americas was $301.0 million, an 18 percent increase over the same period of the prior year. This included Brightree revenue of $33.1 million. Excluding Brightree, revenue in the Americas was $267.9 million, a 5 percent increase over the prior year. Revenue in combined EMEA and APAC was $164.5 million, an increase of 5 percent on a constant currency basis compared to the same period of the prior year.

Gross margin in the first quarter was 57.8 percent, which included a field safety notification expense of $5.1 million relating to the battery in our Astral ventilation device. Excluding the field safety notification expense, the gross margin for Q1 FY17 was 58.9 percent, higher than the prior year’s quarter, mainly due to manufacturing and procurement efficiencies and an incremental contribution from the Brightree acquisition, partly offset by changes in product mix and average selling prices.

Income from operations for the quarter was $94.1 million, a 4 percent decline compared with the quarter ended September 30, 2015. Non-GAAP income from operations for the quarter was $111.0 million, an 11 percent increase compared to the same period of the prior year.

Selling, general and administrative expenses were $128.9 million, a 16 percent increase over the same period in the prior year, or a 15 percent increase on a constant currency basis. SG&A expenses increased to 27.7 percent of revenue in the quarter, compared with 27.0 percent reported in the quarter ended September 30, 2015.


Research and development expenses were $34.4 million, or 7.4 percent of revenue. R&D expenses increased by 27 percent compared with the same period last year, or a 21 percent increase on a constant currency basis.

Amortization of acquired intangible assets was $11.7 million during the quarter, an increase of $9.4 million compared with the same period last year. The increase in amortization of acquired intangible assets was primarily due to the amortization expense associated with our recent acquisitions, in particular Brightree, Curative and Inova. Stock-based compensation costs incurred during the quarter of $12.0 million consisted of expenses associated with employee equity grants, and our employee stock purchase plan.

Net income for the quarter was $76.1 million, an 8 percent decrease compared to the same period of the prior year. Non-GAAP net income was $87.7 million, a 4 percent increase compared to the prior year. Non-GAAP measures adjust for amortization of acquired intangibles and the Astral battery field safety notification expenses. GAAP diluted earnings per share for the quarter decreased 7 percent to $0.54. Non-GAAP diluted earnings per share increased 5 percent to $0.62.

Cash flow from operations for the quarter was $86.2 million compared to net income in the current quarter of $76.1 million.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.33 per share. The dividend will have a record date of November 10, 2016, payable on December 15, 2016. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 8, 2016 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 8, 2016 through November 10, 2016 inclusive.

Webcast details

ResMed will discuss its financial and business results and outlook on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2017 earnings webcast” to register and listen to the live webcast. The online archive of the broadcast will be available on ResMed’s website after the live call. In addition, a telephone replay of the conference call will be available approximately two hours after the call by dialing 855-859-2056 (U.S.) and +1 404-537-3406 (international) and entering a passcode of 88567093. The telephone replay will be available until November 8, 2016.


About ResMed

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

 

Investors:    News Media:
Agnes Lee    Alison Graves
Senior Director, Investor Relations    Director, Global Corporate Communications
(858) 836-5971    (858) 836-6789
investorrelations@resmed.com    news@resmed.com

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

 

    

Three Months Ended

September 30,

 
     2016     2015  

Net revenue

   $ 465,450      $ 411,647   

Cost of sales

     191,196        173,028   

Astral field safety notification expenses (1)

     5,070        —     
  

 

 

   

 

 

 

Gross profit

     269,184        238,619   
  

 

 

   

 

 

 

Operating expenses

    

Selling, general and administrative

     128,851        111,095   

Research and development

     34,446        27,192   

Amortization of acquired intangible assets

     11,741        2,307   
  

 

 

   

 

 

 

Total operating expenses

     175,038        140,594   
  

 

 

   

 

 

 

Income from operations (1)

     94,146        98,025   
  

 

 

   

 

 

 

Other income (expenses), net:

    

Interest income (expense), net

     (2,493     3,422   

Other, net

     1,272        (2,003
  

 

 

   

 

 

 

Total other income (expense), net

     (1,221     1,419   
  

 

 

   

 

 

 

Income before income taxes

     92,925        99,444   

Income taxes

     16,818        16,527   
  

 

 

   

 

 

 

Net income (1)

   $ 76,107      $ 82,917   
  

 

 

   

 

 

 

Basic earnings per share

   $ 0.54      $ 0.59   

Diluted earnings per share

   $ 0.54      $ 0.58   

Non-GAAP diluted earnings per share (1)

   $ 0.62      $ 0.59   

Basic shares outstanding

     140,785        140,309   

Diluted shares outstanding

     142,090        142,280   

 

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited - In thousands)

 

     September 30,     June 30,  
     2016     2016  

ASSETS:

    

Current assets:

    

Cash and cash equivalents

   $ 781,658      $ 731,434   

Accounts receivable, net

     347,137        382,086   

Inventories

     253,828        224,456   

Prepayments and other current assets

     92,229        81,743   
  

 

 

   

 

 

 

Total current assets

     1,474,852        1,419,719   
  

 

 

   

 

 

 

Property, plant and equipment, net

     390,797        384,276   

Goodwill

     1,062,758        1,059,245   

Other intangibles, net

     289,673        299,808   

Deferred income taxes and other non-current assets

     104,184        93,657   
  

 

 

   

 

 

 

Total non-current assets

     1,847,412        1,836,986   
  

 

 

   

 

 

 

Total assets

   $ 3,322,264      $ 3,256,705   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY:

    

Current liabilities:

    

Accounts payable

   $ 80,489      $ 92,571   

Accrued expenses

     153,969        156,805   

Deferred revenue

     47,665        50,009   

Income taxes payable

     38,807        39,166   

Short-term debt

     299,625        299,438   
  

 

 

   

 

 

 

Total current liabilities

     620,555        637,989   
  

 

 

   

 

 

 

Non-current liabilities:

    

Deferred income taxes

     8,920        9,061   

Deferred revenue

     45,736        40,281   

Other long term liabilities

     974        1,211   

Long-term debt

     873,511        873,332   
  

 

 

   

 

 

 

Total non-current liabilities

     929,141        923,885   
  

 

 

   

 

 

 

Total liabilities

     1,549,696        1,561,874   
  

 

 

   

 

 

 

STOCKHOLDERS’ EQUITY:

    

Common stock

     564        563   

Additional paid-in capital

     1,321,522        1,303,238   

Retained earnings

     2,190,028        2,160,299   

Treasury stock

     (1,546,611     (1,546,611

Accumulated other comprehensive income

     (192,935     (222,658
  

 

 

   

 

 

 

Total stockholders’ equity

   $ 1,772,568      $ 1,694,831   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 3,322,264      $ 3,256,705   
  

 

 

   

 

 

 

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited - In thousands)

 

    

Three Months Ended

September 30,

 
     2016     2015  

Cash flows from operating activities:

    

Net income

   $ 76,107      $ 82,917   

Adjustment to reconcile net income to cash provided by operating activities:

    

Depreciation and amortization

     27,775        18,403   

Stock-based compensation costs

     12,049        12,383   

Changes in operating assets and liabilities, net of effect of acquisitions:

    

Accounts receivable, net

     36,207        30,498   

Inventories, net

     (28,073     (17,194

Prepaid expenses, net deferred income taxes and other current assets

     (19,115     (3,526

Accounts payable, accrued expenses and other liabilities

     (18,707     1,127   
  

 

 

   

 

 

 

Net cash provided by operating activities

     86,243        124,608   
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchases of property, plant and equipment

     (14,560     (16,403

Patent registration costs

     (2,471     (2,423

Business acquisitions, net of cash acquired

     (3,090     —     

Investments in cost-method investments

     (2,758     (4,582

Proceeds / (Payments) on maturity of foreign currency contracts

     9,710        (39,341
  

 

 

   

 

 

 

Net cash used in investing activities

     (13,169     (62,749
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from issuance of common stock, net

     6,330        4,352   

Purchases of treasury stock

     —          (57,857

Proceeds from borrowings, net of borrowing costs

     25,000        200,000   

Repayment of borrowings

     (25,000     (8

Dividends paid

     (46,378     (42,079
  

 

 

   

 

 

 

Net cash (used in) / provided by financing activities

     (40,048     104,408   
  

 

 

   

 

 

 

Effect of exchange rate changes on cash

     17,198        (61,463
  

 

 

   

 

 

 

Net increase / (decrease) in cash and cash equivalents

     50,224        104,804   

Cash and cash equivalents at beginning of period

     731,434        717,249   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 781,658      $ 822,053   
  

 

 

   

 

 

 

 

- More -


Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US$ thousands, except share and per share data)

The measure, “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

    

Three Months Ended

September 30,

 
     2016      2015  

GAAP income from operations

     94,146         98,025   

Astral battery field safety notification expenses (A)

     5,070         —     

Amortization of acquired intangible assets (A)

     11,741         2,307   
  

 

 

    

 

 

 

Non-GAAP operating income

     110,957         100,332   
  

 

 

    

 

 

 

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

    

Three Months Ended

September 30,

 
     2016      2015  

GAAP net income

     76,107         82,917   

Astral battery field safety notification expenses, net of tax (A)

     3,549         —     

Amortization of acquired intangible assets, net of tax (A)

     8,006         1,717   
  

 

 

    

 

 

 

Non-GAAP net income (A)

     87,662         84,634   
  

 

 

    

 

 

 

Diluted shares outstanding

     142,090         142,280   
  

 

 

    

 

 

 

GAAP diluted earnings per share

   $ 0.54       $ 0.58   
  

 

 

    

 

 

 

Non-GAAP diluted earnings per share (A)

   $ 0.62       $ 0.59   
  

 

 

    

 

 

 

 

(A) ResMed adjusts for the impact of the Astral battery field safety notification expenses and amortization of acquired intangible assets from their evaluation of ongoing operations and believes investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed’s performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

 

- End -